Global Bronchodilators Market, By Type (Beta-Adrenergic Bronchodilators, Anticholinergic Bronchodilators, Xanthine Derivatives, Others), Indication (Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Reactions, Breathing Problem, Others), Route of Administration (Oral, Parenteral Inhalational, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) – Industry Trends and Forecast to 2029
Bronchodilators Market Analysis and Size
The global bronchodilators market is expected to witness significant growth during the forecast period. Growing cases of asthma and COPD which causes breathing problem is driving the bronchodilators market. However, increased usage of bronchodilators for treating cystic fibrosis will also boost the market. The market growth is expanding and is expected to rise high in the forecast period.
Data Bridge Market Research analyses a growth rate in the global bronchodilators market in the forecast period 2022-2029. The expected CAGR of global bronchodilators market is tend to be around 5.50% in the mentioned forecast period. The market was valued at USD 32.3 billion in 2021, and it would grow upto USD 49.57 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Bronchodilators are the agents that open or dilate the bronchial tubes airways of the lungs via relaxing the bronchial muscles. Bronchodilators are also used to reduce mucus from the lungs. They are administered through nebulizer to patients suffering from chronic respiratory disorders.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Beta-Adrenergic Bronchodilators, Anticholinergic Bronchodilators, Xanthine Derivatives, Others), Indication (Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Reactions, Breathing Problem, Others), Route of Administration (Oral, Parenteral Inhalational, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Bayer AG (Germany), Teva Pharmaceutical Industries Ltd. (Israel), Sun Pharmaceutical Industries Ltd. (India), Hikma Pharmaceutical PLC (U.S.), Amneal Pharmaceuticals LLC. (U.K.), Aurobindo Pharma (India), Johnsons & Johnsons Services Pvt Ltd (U.S.), GSK Plc (U.S.), Thermo Fisher Scientific (U.S.), Siemens (Germany)
|
|
Market Opportunities
|
|
Global Bronchodilators Market Dynamics
Drivers
- Increasing Prevalence of COPD
Increased prevalence of COPD is a major factor driving the market growth. As per a June 2021 update WHO, chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, causing 3.23 million deaths in 2019. Thus, the increasing burden of COPD leads to increasing demand for bronchodilators.
- Rising Incidence of Asthma
Per the Centers for Disease and Control of Infection records (2014), there was a diagnosis of 17.7 million asthma patients, out of which, there were 3,651 deaths and the majority were women. As per the reports of WHO, in 2012, more than 3 million people died due to COPD, which was 6% of all deaths globally.
Opportunities
- Rising Prevalence of Smoking
Smoking is still the leading cause of preventable disease and death in the United States, accounting for over 480,000 deaths per year, or roughly one in every five deaths. Cigarette smoking was most prevalent among people aged 25-44 and 45-64. As a result, it causes chronic bronchitis and opens up new market opportunities.
- Advanced Clinical Research and Innovative Strategies
Several market players are engaged in the implementation of strategic initiatives, thereby contributing to market growth. Major players within the bronchodilators market are investing widely to develop varied nebulizers and inhalers that will provide easy access to patients. Ultrasonic nebulizers consist of advanced technology which are available in markets today that creates opportunity for the market.
Restraints/Challenges
- Lack of Awareness
Lack of patient awareness about the disease and differentiated symptoms could curb the growth of the global bronchodilators market over a forecast period.
- High Cost
The huge expenditure required for treating chronic bronchitis surely hamper the market growth.
This global bronchodilators market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global bronchodilators market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Bronchodilators Market Scope
The global bronchodilators market is segmented on the basis of type, indication, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Beta-Adrenergic Bronchodilators
- Anticholinergic Bronchodilators
- Xanthine Derivatives
- Others
Indication
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Allergic Reactions
- Breathing Problem
- Others
Route of Administration
- Oral
- Parenteral Inhalational
- Others
End-Users
- Hospitals
- Specialty Clinics
- Others
Distribution Channel
- Hospitals
- Specialty Clinics
- Others
Bronchodilators Market Regional Analysis/Insights
The global bronchodilators market is analysed and market size insights and trends are provided by type, indication, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global bronchodilators market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America holds the largest market share due to the increasing geriatric population, and increasing initiatives the pharmaceutical organizations took to generate novel formulation.
Europe is expected to account for the largest market share over coming years for the global bronchodilators market due to increased respiratory infection & related disorders.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Bronchodilators Market Share Analysis
The global bronchodilators market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global bronchodilators market
Key players operating in the global bronchodilators market include:
- Bayer AG (Germany)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sun Pharmaceutical Industries Ltd. (India)
- Hikma Pharmaceutical PLC (U.S.)
- Amneal Pharmaceuticals LLC. (U.K.)
- Aurobindo Pharma (India)
- Johnsons & Johnsons Services Pvt Ltd (U.S.)
- GSK Plc (U.S.)
- Thermo Fisher Scientific (U.S.)
- Siemens (Germany)
SKU-